切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2014, Vol. 02 ›› Issue (03) : 179 -184. doi: 10.3877/cma.j.issn.2095-5820.03.011

新技术与新进展

循环肿瘤细胞检测及临床应用价值
郭玮1, 孙云帆2, 潘柏申1, 樊嘉3,2,()   
  1. 1.200032 上海,复旦大学附属中山医院检验科
    2.200032 上海,复旦大学肝癌研究所
    3.200032 上海,复旦大学附属中山医院肝外科
  • 收稿日期:2014-08-01 出版日期:2014-08-28
  • 通信作者: 樊嘉
  • 基金资助:
    “十二五”国家重大科技专项(2013ZX10002010003)上海市科委医学引导类科技项目(134119a1201)癌变与侵袭原理教育部重点实验室开放课题资助(KLCCI2014-3)

Detection and clinical application of circulating tumor cells

Wei Guo1, Yunfan Sun2, Baishen Pan1, Jia Fan3,()   

  1. 1.Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    2.Liver Cancer Institute, Fudan University, Shanghai 200032, China
    3.Department of Liver Surgery, Zhongshan Hospital; Liver Cancer Institute, Fudan University, Shanghai 200032, China,
  • Received:2014-08-01 Published:2014-08-28
  • Corresponding author: Jia Fan
引用本文:

郭玮, 孙云帆, 潘柏申, 樊嘉. 循环肿瘤细胞检测及临床应用价值[J/OL]. 中华临床实验室管理电子杂志, 2014, 02(03): 179-184.

Wei Guo, Yunfan Sun, Baishen Pan, Jia Fan. Detection and clinical application of circulating tumor cells[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2014, 02(03): 179-184.

循环肿瘤细胞(circulating tumor cells,CTC)作为“液体活检”标志用于肿瘤患者实时动态监测。随着分离、富集和检测技术的发展,已经能够在外周血中检测到单个CTC。近几年来,关于循环肿瘤细胞的研究受到多方关注。已有大量证据提示CTC与预后的关系,此外,对肿瘤微转移早期诊断和分期、疗效监测及个体化医疗更具临床价值。许多针对早期和转移性肿瘤的临床试验将CTC作为监测指标,并联合其他平行试验研究CTC分子特征的临床价值。CTC作为实时监测肿瘤治疗反应的指标广泛应用于临床,为确定肿瘤患者治疗策略提供依据。

Circulating tumor cells (CTC) analysis as a liquid biopsy could be carried out in a realtime manner. With the development of the technology in enrichment, separation, and detection, one single tumor cell lurking among a billion normal hematopoietic cells can be detected. There is much evidence regarding the ability to detect CTC and their prognostic relevance. The application in cancer diagnosis and staging, therapeutic response monitoring, and personalized medicine is clinically even more meaningful. Recently, CTC was used as a monitoring parameter in many clinical trials in diagnosing the early and metastatic cancer. Numerous translational studies attempting their molecular characterization are under way. CTC as a tool to monitor treatment response could be widely implemented, especially leading to more powerful treatment strategies for cancer patients.

1
Zong C, Lu S, Chapman A R, et al. Genome-wide detection of singlenucleotide and copy-number variations of a single human cell [J].Science, 2012, 338(6114): 1622-1626.
2
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells,disease progression, and survival in metastatic breast cancer [J]. N Engl J Med, 2004, 351(8): 781-791.
3
Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis [J].Science, 2011, 331(6024): 1559-1564.
4
Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2008,6(19): 3213-3221.
5
de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer [J]. Clin Cancer Res, 2008, 14(19): 6302-6309.
6
Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation [J]. Cell, 2012, 148(1-2): 349-361.
7
Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay [J]. Nat Biotechnol, 2013,31(6): 539-544.
8
Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90.
9
Gangopadhyay S, Nandy A, Hor P, et al. Breast cancer stem cells: a novel therapeutic target [J]. Clin Breast Cancer, 2013, 13(1): 7-15.
10
Boice JD Jr, Cohen SS, Mumma MT, et al. Mortality among mound workers exposed to polonium-210 and other sources of radiation,1944-1979 [J]. Radiat Res, 2014, 181(2): 208-228.
11
Zhang Y, Li J, Cao L, et al. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives [J]. Semin Oncol, 2012, 39(4): 449-460.
12
Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90.
13
Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected [J]. J Clin Oncol, 2011,29(12): 1508-1511.
14
那彦群, 郭震华, 主编. 实用泌尿外科学 [M]. 北京: 人民卫生出版社, 2011: 357.
15
张建伟, 孙跃民, 边志民, 等. 小胰腺癌的诊断和预后[J]. 中华肿瘤杂志, 2009, 31(5): 375-379.
16
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis [J]. Lancet Oncol, 2009, 10(1): 35-43.
17
Pantel K, Alix-Panabières C, Riethdorf S. Cancer micrometastases [J].Nat Rev Clin Oncol, 2009, 6(6): 339-351.
18
Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer [J]. N Engl J Med, 2005, 353(8): 793-802.
19
Bevilacqua S, Gallo M, Franco R, et al. A “live” biopsy in a smallcell lung cancer patient by detection of circulating tumor cells [J].Lung Cancer, 2009, 65(1): 123-125.
20
Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer [J]. Clin Cancer Res, 2009,15(22): 6980-6986.
21
Shen C, Hu L, Xia L, et al. Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients [J]. Jpn J Clin Oncol, 2008, 38(11): 770-776.
22
孙俊宁, 梁小波, 刘永昌. 结直肠癌患者血液循环中癌细胞微转移的观察[J]. 中国药物与临床, 2008, 8(4): 274-276.
23
Sastre J, Maestro ML, Puente J, et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables [J].Ann Oncol, 2008, 19(5): 935-938.
24
Xu W, Cao L, Chen L, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy [J]. Clin Cancer Res, 2011, 17(11): 3783-3793.
25
Schulze K, Gasch C, Staufer K, et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma [J]. Int J Cancer, 2013, 133(9): 2165-2171.
26
Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer [J]. J Clin Oncol, 2011, 29(12): 1556-1563.
27
Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and metaanalysis [J]. BMC Cancer, 2011, 11: 336.
28
Resel Folkersma L, San José Manso L, Galante Romo I, et al. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer [J]. Urology, 2012, 80(6): 1328-1332.
29
Khan MS, Kirkwood A, Tsigani T, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors [J]. J Clin Oncol, 2013,31(3): 365-372.
30
Bölke E, Orth K, Gerber PA, et al. Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients [J]. Eur J Med Res, 2009, 14(8): 359-363.
31
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells,disease progression, and survival in metastatic breast cancer [J]. N Engl J Med, 2004, 351(8): 781-791.
32
Nakagawa T, Martinez SR, Goto Y, et al. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes [J]. Clin Cancer Res, 2007, 13(14): 4105-4110.
33
Rack BK, Schindlbeck C, Andergassen U, et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS trial [J]. J Clin Oncol, 2010, 28: 15s.
34
Resel Folkersma L, Olivier Gómez C, San José Manso L, et al.Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation [J]. Arch Esp Urol, 2010, 63(1): 23-31.
35
Moreno JG, Miller MC, Gross S, et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer [J]. Urology, 2005,65(4): 713-718.
36
Okegawa T, Nutahara K, Higashihara E, et al. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer [J]. Int J Urol, 2010, 17(5):466-475.
37
Goodman OB Jr, Fink LM, Symanowski JT, et al. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors [J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(6): 1904-1913.
38
Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea [J]. Stat Med, 2006, 25(1):127-141.
39
Botteri E, Sandri MT, Bagnardi V, et al. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer [J]. Breast Cancer Res Treat, 2010, 122(1): 211-217.
40
Khoja L, Lorigan P, Zhou C, et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma [J]. J Invest Dermatol,2013, 133(6): 1582-1590.
41
Naito T, Tanaka F, Ono A, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer [J]. J Thorac Oncol, 2012,7(3): 512-519.
42
Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer [J]. J Clin Oncol, 2012, 30(5): 525-532.
43
Wu C, Hao H, Li L, et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients [J]. J Thorac Oncol, 2009, 4(1): 30-36.
44
Sun YF, Xu Y, Yang XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection [J]. Hepatology,2013, 57(4): 1458-1468.
45
Matsusaka S, Chìn K, Ogura M, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer [J]. Cancer Sci, 2010, 101(4): 1067-1071.
46
Yokobori T, Iinuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis [J].Cancer Res, 2013, 73(7): 2059-2069.
47
Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer [J]. J Clin Oncol, 2009, 27(31): 5153-5159.
48
Contractor K1, Aboagye EO, Jacob J, et al. Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and 18F 3´-deoxy-3´-fluorothymidine PET: a pilot study [J].Biomark Med, 2012, 6(2): 231-233.
49
Lu CY, Tsai HL, Uen YH, et al. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer [J]. Br J Cancer, 2013, 108(4):791-797.
50
Olmos D, Arkenau HT, Ang JE, et al. Circulating tumour cell (CTC)counts as intermediate end points in castration-resistant prostate cancer(CRPC): a single-centre experience [J]. Ann Oncol, 2009, 20(1): 27-33.
51
Scher HI, Jia X, de Bono JS, et al. Circulating tumor cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data [J]. Lancet Oncol, 2009, 10(3): 233-239.
52
Pachmann K, Camara O, Kavallaris A, et al. Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring [J]. Breast Cancer Res, 2005, 7(6): R975-R979.
53
Nolé F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications [J]. Ann Oncol, 2008, 19(5): 891-897.
54
Hartkopf AD, Wagner P, Wallwiener D, et al. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer [J]. Anticancer Res, 2011, 31(3): 979-984.
55
Fan ST, Yang ZF, Ho DW, et al. Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study [J]. Ann Surg, 2011, 254(4): 569-576.
56
Guo W, Yang XR, Sun Y, et al. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR based platform [J].Clin Cancer Res, 2014, 20(18): 4794-4805.
57
Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer:association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib [J]. Clin Cancer Res, 2012, 18(8): 2391-2401.
58
Sakaizawa K, Goto Y, Kiniwa Y, et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level [J]. Br J Cancer, 2012, 106(5): 939-946.
59
Miyamoto DT, Lee RJ, Stott SL, et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer [J]. Cancer Discov, 2012, 2(11): 995-1003.
60
Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells [J]. N Engl J Med, 2008, 359(4):366-377.
61
Fabbri F, Carloni S, Zoli W, et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs [J]. Cancer Lett, 2013, 335(1): 225-231.
62
Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study [J]. Eur Urol, 2012,61(4): 810-817.
63
Hayashi N, Nakamura S, Tokuda Y, et al. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer [J]. Int J Clin Oncol, 2012, 17(2): 96-104.
64
Pailler E, Adam J, Barthélémy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive nonsmall-cell lung cancer [J]. J Clin Oncol, 2013, 31(18): 2273-2281.
65
Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses [J]. Proc Natl Acad Sci U S A,2004, 101(25): 9393-9398.
66
Pantel K, Alix-Panabières C, Riethdorf S. Cancer micrometastases [J].Nat Rev Clin Oncol, 2009, 6(6): 339-351.
67
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med, 2009,361(10): 947-957.
68
Wang D, Bodovitz S. Single cell analysis: the new frontier in “omics”[J]. Trends Biotechnol, 2010, 28(6): 281-290.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[7] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[8] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[12] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[13] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?